Drugs & Targets FDA grants accelerated approval to sevabertinib for locally advanced or metastatic non-squamous NSCLC September 18, 2026Vol.52 No.34
Cancer Policy Heidi Overton selected as FDA commissioner; Jared Seehafer named inaugural Deputy Commissioner for Technology and AI September 11, 2026Vol.52 No.33By Claire Marie Porter
Drugs & Targets FDA grants accelerated approval to iberdomide combination for MM September 11, 2026Vol.52 No.33
Drugs & Targets FDA grants accelerated approval to camizestrant combination for HR+ metastatic breast cancer September 11, 2026Vol.52 No.33
Drugs & Targets FDA grants accelerated approval to sevabertinib for locally advanced or metastatic non-squamous NSCLC September 11, 2026Vol.52 No.33
Drugs & Targets FDA approves first-of-its-kind drug rusfertide for polycythemia vera September 11, 2026Vol.52 No.33
Podcast Raja Flores says oncology is loose with staging jargon, and now “it’s confusing my patients.” August 19, 2026
Drugs & TargetsFree FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma August 14, 2026Vol.52 No.32
Drugs & TargetsFree FDA advisory committee to vote on GRAIL’s multi-cancer detection test, Galleri August 14, 2026Vol.52 No.32
Drugs & TargetsFree FDA approves companion diagnostic supporting patients with advanced melanoma August 14, 2026Vol.52 No.32
